Finance
L'Oreal to buy majority stake in British skincare brand Medik8
Published by Global Banking & Finance Review®
Posted on June 9, 2025
2 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on June 9, 2025
2 min readLast updated: January 23, 2026
L'Oreal acquires a majority stake in Medik8, enhancing its dermatological skincare market position. The deal values Medik8 at around 1 billion euros.
PARIS/LONDON (Reuters) -L'Oreal has agreed to acquire a majority stake in British skincare brand Medik8, boosting the French cosmetics giant's position in the fast-growing dermatological skincare market.
Neither L'Oreal nor UK-based private equity firm Inflexion, which is selling the stake, disclosed the terms of the deal in separate statements on Monday.
A person with knowledge of the situation said the deal puts Medik8's enterprise value at around 1 billion euros.
"This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with a proven track record of success, with strong potential for global growth," L'Oreal said in its statement.
Sales growth at L'Oreal's luxury division, its second largest which houses MiuMiu perfume, Lancome skincare and Aesop cleansers, slowed to 2.7% last year as higher inflation prompted shoppers to opt for less expensive brands.
That was the lowest growth of all of L'Oreal's segments, but outpaced the beauty division of luxury rival LVMH.
Inflexion will retain a minority shareholding in Medik8, which focuses on vitamin A-based anti-ageing creams and serums, although L'Oreal has secured rights to buy out minority shareholders in full.
At 0810 GMT, L'Oreal's share price was down 0.2%, in line with a broader fall for France's CAC 40.
(Reporting by Dominique Patton, Kate Entringer, Mimosa Spencer and Anousha Sakoui; Writing by Benoit Van Overstraeten; Editing by Kirsten Donovan)
The deal puts Medik8's enterprise value at around 1 billion euros.
Medik8 focuses on vitamin A-based anti-ageing creams and serums.
This acquisition further strengthens L'Oreal's luxe portfolio, adding a premium science-backed skincare brand with strong potential for global growth.
The stake is being sold by the UK-based private equity firm Inflexion.
Sales growth at L'Oreal's luxury division slowed to 2.7% last year.
Explore more articles in the Finance category
